Prelude Therapeutics Advances Pipeline with Key Clinical Milestones and Extended Cash Runway — Prelude Therapeutics, Incorporated

Event summary

Prelude Therapeutics expects to initiate a Phase 1 study of PRT13722, a first-in-class KAT6A degrader for HR+ breast cancer, in Q4 2026.
Preclinical data for PRT13722 was presented at the AACR Annual Meeting 2026.
Enrollment continues in the Phase 1 study of PRT12396, a mutant-selective JAK2V617F inhibitor, for polycythemia vera and myelofibrosis.
Cash runway extended to Q2 2028 with $155.2 million in cash and marketable securities as of June 30, 2026.

The big picture

Prelude Therapeutics is advancing its precision oncology pipeline with differentiated approaches to clinically validated targets. The company's focus on targeted protein degradation and mutant-selective inhibitors aligns with broader industry trends toward more precise and effective cancer treatments. With an extended cash runway, Prelude aims to sustain its R&D efforts while navigating the competitive landscape of oncology therapeutics.

What we're watching

Clinical Execution: The pace at which Prelude can initiate and complete the Phase 1 study of PRT13722 will determine its competitive positioning in HR+ breast cancer.
Financial Sustainability: Whether Prelude's current cash runway is sufficient to support its pipeline through potential future clinical trials and regulatory milestones.
Partnership Dynamics: How the exclusive option agreement with Incyte for the JAK2V617F inhibitor program will impact Prelude’s strategic flexibility and financial outlook.